株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

特発性肺線維症(IPF) - 市場洞察、疫学、市場予測 2028年

Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 650525
出版日 ページ情報 英文 196 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
特発性肺線維症(IPF) - 市場洞察、疫学、市場予測 2028年 Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年07月01日 ページ情報: 英文 196 Pages
概要

主要8カ国(米国、カナダ、英国、ドイツ、フランス、イタリア、スペイン、日本)の突発性肺繊維症(IPF)の有病数は2017年に22万9,170人、その市場規模は16億4,440万米ドルと推計されています。

当レポートでは、主要8カ国(米国、カナダ、英国、ドイツ、フランス、イタリア、スペイン、日本)の突発性肺繊維症(IPF)市場を調査し、疾病の概要や現行の治療法、上市済み治療薬、新薬および候補薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 主な洞察

第2章 突発性肺繊維症(IPF)の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 突発性肺線維症(IPF)の病期分類
  • 危険因子
  • 症状
  • 病因
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要8カ国の診断数
  • 国別の疫学
    • 米国
    • カナダ
    • EU5カ国
      • フランス
      • ドイツ
      • イタリア
      • スペイン
      • 英国
    • 日本

第5章 現行の治療法

  • ATS/ERS/JRS/ALAT診療ガイドライン:突発性肺線維症の治療

第6章 アンメットニーズ

第7章 上市済み製品

  • Esbriet(ピルフェニドン):InterMune Inc.
    • 製品概要
    • 規制のマイルストーン
    • 長所と短所
    • 安全性と有効性
    • 副作用
    • 製品プロファイル
  • Ofev(Nintedanib):Boehringer Ingelheim Pharma GmbH & Co.
    • 安全性と有効性
    • 副作用

第8章 新薬

  • キークロスコンペティション
  • トロンボモデュリンアルファ:旭化成ファーマ
    • 製品概要
    • 製品プロファイル
    • 臨床開発
    • 臨床試験情報
    • 安全性と有効性
  • GLPG1690:Galapagos NV
    • 規制のマイルストーン
    • その他の開発活動

第9章 有望な候補薬

  • CC-90001:Celgene Corporation
    • 製品概要
    • 製品プロファイル
    • 臨床開発
    • 安全性と有効性
  • LT-1001:LTT Bio-Pharma
    • 規制のマイルストーン
    • その他の開発活動
  • BG00011:Biogen Inc
    • 臨床試験情報

第10章 突発性肺線維症(IPF)市場の分析

  • 主な調査結果
  • 主要8カ国の総市場規模
  • 主要8カ国の市場規模:治療薬別
  • 国別の市場規模
    • 米国
    • カナダ
    • EU5カ国
      • ドイツ
      • フランス
      • イタリア
      • 英国
      • スペイン
    • 日本

第11章 市場の成長要因

第12章 市場の障壁

第13章 付録

  • 調査手法

第14章 DelveInsightのサービス内容

第15章 免責事項

第16章 DelveInsightについて

図表

List of Tables

  • Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis
  • Table 2: The GAP (Gender, Age, and Physiology) score
  • Table 3: The GAP index and staging system
  • Table 4: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 5: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 6: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 7: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 8: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 9: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 10: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 11: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 12: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 13: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 14: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 15: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 16: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 17: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 18: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 19: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 20: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 21: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 22: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 23: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 24: The United Kingdom, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 25: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 26: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 27: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 28: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 29: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 30: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 31: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 32: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 33: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 34: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 35: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Table 36: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 37: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Table 38: Key Cross Analysis of Emerging Therapies
  • Table 39: ART-123, Clinical Trial Description, 2019
  • Table 40: Pamrevlumab, Clinical Trial Description, 2019
  • Table 41: KD025, Clinical Trial Description, 2019
  • Table 42: PRM151, Clinical Trial Description, 2019
  • Table 43: GLPG1690, Clinical Trial Description, 2019
  • Table 44: CC90001, Clinical Trial Description, 2019
  • Table 45: LT-1001, Clinical Trial Description, 2019
  • Table 46: BG00011, Clinical Trial Description, 2019
  • Table 47: PBI4050, Clinical Trial Description, 2019
  • Table 49: Tipelukast, Clinical Trial Description, 2019
  • Table 50: TD-139, Clinical Trial Description, 2019
  • Table 51: VAY736, Clinical Trial Description, 2019
  • Table 52: TAS-115, Clinical Trial Description, 2019
  • Table 53: ND-L02-s0201, Clinical Trial Description, 2019
  • Table 54: Nalbuphine ER, Clinical Trial Description, 2019
  • Table 55: RVT-1601, Clinical Trial Description, 2019
  • Table 56: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028)
  • Table 57: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028)
  • Table 58: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028)
  • Table 59: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028)
  • Table 60: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028)
  • Table 61: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028)
  • Table 62: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028)
  • Table 63: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028)
  • Table 64: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028)
  • Table 65: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028)
  • Table 66: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028)
  • Table 67: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK in USD Million (2017-2028)
  • Table 68: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028)
  • Table 69: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028)
  • Table 70: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028)
  • Table 71:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028)
  • Table 72: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028)
  • Table 73:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028)

List of Figures

  • Figure 1: Risk factors associated with IPF
  • Figure 2: IPF associated clubbing of the fingertips
  • Figure 3: Stages of the pathogenesis of IPF
  • Figure 4: A schematic representing the current model for the pathogenesis of IPF
  • Figure 5: Possible mechanisms of fibrogenesis in IPF
  • Figure 6: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities
  • Figure 7: Subpleural honeycombing in IPF diagnosed patients
  • Figure 8: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF
  • Figure 9: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 10: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 11: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 12: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 13: The United States, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 14: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 15: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 16: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 17: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 18: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 19: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 20: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 21: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 22: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 23: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 24: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 25: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 26: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 27: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 28: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 29: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 30: The United Kingdom, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 31: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 32: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 33: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 34: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 35: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 36: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 37: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 38: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 39: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 40: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028
  • Figure 41: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 42: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028
  • Figure 43: Suggested Algorithm for IPF Treatment
  • Figure 44: Unmet Needs of IPF
  • Figure 45: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028)
  • Figure 46: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028)
  • Figure 47: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028)
  • Figure 48: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028)
  • Figure 49: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028)
  • Figure 50: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028)
  • Figure 51: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028)
  • Figure 52: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028)
  • Figure 53: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028)
  • Figure 54: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028)
  • Figure 55: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028)
  • Figure 56: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in The UK in USD Million (2017-2028)
  • Figure 57: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028)
  • Figure 58: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028)
  • Figure 59: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028)
  • Figure 60: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028)
  • Figure 61: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028)
  • Figure 62: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028)
  • Figure 63: Market Drivers of IPF
  • Figure 64: Market Barriers of IPF
目次
Product Code: DIMI0111

DelveInsight's 'Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, Canada, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis from 2017 to 2028 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • Canada

Study Period: 2017-2028

Idiopathic Pulmonary Fibrosis (IPF) - Disease Understanding and Treatment Algorithm

The DelveInsight Idiopathic Pulmonary Fibrosis market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, staging, symptoms, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for etiology in the US, Europe, and Japan.

Idiopathic Pulmonary Fibrosis (IPF) Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent diagnosed cases, severity-specific prevalent cases and gender and age -specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Canada, and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in G8 markets was found to be 229,170 in 2017. 

Idiopathic Pulmonary Fibrosis Drug Chapters

This segment of the IPF Drug report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs and biosimilars. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

At present, therapeutic approach of IPF involves both non-pharmacological and pharmacological strategies. Non-pharmacological approach include supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation and palliative care services. While the pharmacological treatment options include corticosteroids, immunosuppressive/cytotoxic agents (azathioprine, cyclophosphamide) and anti-fibrotic agents (e.g., colchicine or d-penicillamine) alone or in combination. At present two therapies have obtained approval for treatment of IPF that include antifibrotic drugs (Pirfenidone and Nintedanib). Detailed chapter for upcoming therapies like Thrombomodulin Alfa (Asahi Kasei Pharma Corporation), Pamrevlumab (FibroGen), KD025 (Kadmon Corporation, LLCs) etc. and other promising therapies such as CC-90001 (Celgene Corporation), LT1001 (LTT Bio-Pharma), BG00011 (Biogen Inc) etc. have also been covered in the report.

Idiopathic Pulmonary Fibrosis Market Outlook

The IPF market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 8G was found to be USD 1644.4 million in 2017.

Idiopathic Pulmonary Fibrosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Idiopathic Pulmonary Fibrosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Idiopathic Pulmonary Fibrosis Report Key Strengths

  • 10 Year Forecast
  • G8 Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Idiopathic Pulmonary Fibrosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market
  • To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.

Table of Contents

1. Key Insights

2. IPF Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of IPF in 2017
  • 2.2. Market Share (%) Distribution of IPF in 2028

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

  • 3.1. Introduction
  • 3.2. Staging of IPF
  • 3.3. Risk Factors & Disease Causes
  • 3.4. Symptoms
  • 3.5. Pathogenesis
  • 3.6. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. G8 Diagnosed Prevalent Population of IPF
  • 4.3. Country Wise-Epidemiology of IPF
    • 4.3.1. United States
      • 4.3.1.1. Diagnosed Prevalent cases of IPF in the United States
      • 4.3.1.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.1.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.1.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.2. Canada
      • 4.3.2.1. Diagnosed Prevalent cases of IPF in Canada
      • 4.3.2.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.2.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.2.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.3. EU5
      • 4.3.3.1. Diagnosed Prevalent Population of IPF in EU5
    • 4.3.4. France
      • 4.3.4.1. Diagnosed Prevalent Population of IPF
      • 4.3.4.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.4.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.4.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.5. Germany
      • 4.3.5.1. Diagnosed Prevalent Population of IPF
      • 4.3.5.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.5.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.5.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.6. Italy
      • 4.3.6.1. Diagnosed Prevalent Population of IPF
      • 4.3.6.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.6.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.6.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.7. Spain
      • 4.3.7.1. Diagnosed Prevalent Population of IPF
      • 4.3.7.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.7.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.7.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.8. United Kingdom
      • 4.3.8.1. Diagnosed Prevalent Population of IPF
      • 4.3.8.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.8.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.8.4. Age-Specific IPF Diagnosed Prevalence
    • 4.3.9. Japan
      • 4.3.9.1. Diagnosed Prevalent Population of IPF
      • 4.3.9.2. Diagnosed Prevalent Population of IPF by severity
      • 4.3.9.3. Gender-Specific IPF Diagnosed Prevalence
      • 4.3.9.4. Age-Specific IPF Diagnosed Prevalence

5. Current Treatment Practices

  • 5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline)

6. Unmet needs

7. Marketed Products

  • 7.1. Esbriet (Pirfenidone): InterMune Inc.
    • 7.1.1. Product Description
    • 7.1.2. Regulatory Milestones
    • 7.1.3. Advantages & Disadvantages
    • 7.1.4. Safety and Efficacy of Esbriet
    • 7.1.5. Side effects of Esbriet
    • 7.1.6. Product Profile
  • 7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co.
    • 7.2.1. Product Description
    • 7.2.2. Regulatory Milestones
    • 7.2.3. Advantages & Disadvantages
    • 7.2.4. Safety and Efficacy of Ofev
    • 7.2.5. Side effects of Ofev
    • 7.2.6. Product Profile

8. Emerging Therapies

  • 8.1. Key Cross Competition
  • 8.2. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
    • 8.2.1. Drug Description
    • 8.2.2. Product Profile
    • 8.2.3. Clinical Development
    • 8.2.4. Clinical Trials Information
    • 8.2.5. Safety and Efficacy
  • 8.3. GLPG1690: Galapagos NV
    • 8.3.1. Drug Description
    • 8.3.2. Product Profile
    • 8.3.3. Regulatory Milestones
    • 8.3.4. Other Development Activities
    • 8.3.5. Clinical Development
    • 8.3.6. Safety and Efficacy

List To be continued in report

9. Other Promising Candidates

  • 9.1. CC-90001: Celgene Corporation
    • 9.1.1. Drug Description
    • 9.1.2. Product Profile
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
  • 9.2. LT-1001: LTT Bio-Pharma
    • 9.2.1. Drug Description
    • 9.2.2. Product Profile
    • 9.2.3. Regulatory Milestones
    • 9.2.4. Other Development Activities
    • 9.2.5. Clinical Development
    • 9.2.6. Safety and Efficacy
  • 9.3. BG00011: Biogen Inc
    • 9.3.1. Drug Description
    • 9.3.2. Product Profile
    • 9.3.3. Regulatory Milestones
    • 9.3.4. Other Development Activities
    • 9.3.5. Clinical Development
    • 9.3.6. Clinical Trials Information
    • 9.3.7. Safety and Efficacy

List To be continued in report

10. IPF: Market Analysis

  • 10.1. Key Findings
  • 10.2. Total Market Size of IPF in 8G
  • 10.3. Therapy Based Market Size of IPF in 8G
  • 10.4. Market Size of IPF by Country
    • 10.4.1. United States Market Analysis
      • 10.4.1.1. Market Size of IPF in the US
      • 10.4.1.2. Therapy Based Market Size of IPF in the US
    • 10.4.2. EU5 Market Outlook
    • 10.4.3. Germany
      • 10.4.3.1. Market Size of IPF in Germany
      • 10.4.3.2. Therapy Based Market Size of IPF in Germany
    • 10.4.4. France
      • 10.4.4.1. Market Size of IPF in France
      • 10.4.4.2. Therapy Based Market Size of IPF in France
    • 10.4.5. Italy
      • 10.4.5.1. Market Size of IPF in Italy
      • 10.4.5.2. Therapy Based Market Size of IPF in Italy
    • 10.4.6. United Kingdom
      • 10.4.6.1. Market Size of IPF in the UK
      • 10.4.6.2. Therapy Based Market Size of IPF in the UK
    • 10.4.7. Spain
      • 10.4.7.1. Market Size of IPF in Spain
      • 10.4.7.2. Therapy Based Market Size of IPF in Spain
    • 10.4.8. Japan: Market Analysis
      • 10.4.8.1. Market Size of IPF in Japan
      • 10.4.8.2. Therapy Based Market Size of IPF in Japan
    • 10.4.9. Canada: market Analysis
      • 10.4.9.1. Market Size of IPF in Japan
      • 10.4.9.2. Therapy Based Market Size of IPF in Japan

11. Market Drivers of IPF

12. Market Barriers of IPF

13. Appendix

  • 13.1. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

Back to Top